Finally, NFL measurement was included in the historic phase 1–2 trials of the anti-SOD1 antisense oligonucleotide tofersen in patients with ALS due to SOD1 mutations, whose results were published in 2020. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.